XORTX Therapeutics
XRTX
3 hedge funds and large institutions have $6.25K invested in XORTX Therapeutics in 2026 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, reducing their positions, and 5 closing their positions.
0.62% less ownership
Funds ownership: 0.66% → 0.04% (-0.62%)
50% less funds holding
Funds holding: 6 → 3 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
95% less capital invested
Capital invested by funds: $124K → $6.25K (-$117K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KWM
Kingsview Wealth Management
Grants Pass,
Oregon
|
+$7K |
| 2 |
TWC
TD Waterhouse Canada
Toronto,
Ontario, Canada
|
+$21 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
-$109K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$7.08K |
| 3 |
BBA
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
|
-$4.74K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$2K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$787 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KWM
1
Kingsview Wealth Management
Grants Pass,
Oregon
| $6.13K | +$7K | +3,000 | New |
|
|
CA
2
Clearstead Advisors
Cleveland,
Ohio
| $92 | – | – | – |
|
|
TWC
3
TD Waterhouse Canada
Toronto,
Ontario, Canada
| $19 | +$21 | +9 | New |
|
|
DS
4
DRW Securities
Chicago,
Illinois
| – | -$109K | -38,720 | Closed |
|
|
BBA
5
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
| – | -$4.74K | -3,746 | Closed |
|
|
TSS
6
Two Sigma Securities
New York
| – | -$7.08K | -2,519 | Closed |
|
|
7
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$2K | -818 | Closed |
|
|
8
UBS Group
Zurich,
Switzerland
| – | -$787 | -280 | Closed |
|
XRTX Hedge Fund Activity: Q1 2026 in Review
3 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in XORTX Therapeutics (XRTX) for Q1 2026, worth a combined $6.25K — down 95% from $124K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of XRTX and 2 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.
The largest buyer was Kingsview Wealth Management, opening a new position worth an estimated $7K. The largest seller was DRW Securities, exiting entirely with an estimated $109K sold.
- 3 institutional investors held XORTX Therapeutics (XRTX) as of Q1 2026, down from 6 in Q4 2025.
- Funds reported $6.25K of XORTX Therapeutics stock for Q1 2026, down 95% quarter-over-quarter.
- 2 funds opened new XORTX Therapeutics positions in Q1 2026 and 5 closed out, a net change of -3 holders.
- The largest XORTX Therapeutics buyer in Q1 2026 was Kingsview Wealth Management, an estimated $7K added.
- The largest XORTX Therapeutics seller in Q1 2026 was DRW Securities, an estimated $109K sold.
Based on aggregated 13F filings for Q1 2026.